chevron_leftBack
As of 14 June 2026, ProKidney Corp. has a market cap of $551.08M USD, ranking #14483 globally and #2570 in the United States.
It ranks #1286 in the Healthcare sector, and #241 in the Biotechnology industry.
Key Stats
Market Cap
$551.08MUSD
Enterprise Value
$273.02MUSD
Revenue (TTM)
$893.0KUSD
EBITDA (TTM)
-$158.43MUSD
Net Income (TTM)
-$68.99MUSD
PS Ratio
603.6
PB Ratio
1.8
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Bruce Culleton
open_in_new
Employees
231
Founded
2015
Website
prokidney.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -0.3% | -13% | 14% | -13% | -40% | 77% |
News
Loading...
PROK Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
PROK
ProKidney Corp Ordinary Shares - Class A
ISIN: US74291D1046
Shares Out.:
Shares Outstanding:
205.2M1
Shares Float:
56.544M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
1.83 USD | |
|
PROK
(PROK/N)
ProKidney Corp Ordinary Shares - Class A
ISIN: KYG7S53R1049
Shares Out.:
Shares Outstanding:
129.536M1
Shares Float:
94.191M2
|
15.47 MXN | |
|
PROK/N
ProKidney Corp Ordinary Shares - Class A
ISIN: US74291D1046
Shares Out.:
Shares Outstanding:
129.536M1
Shares Float:
94.191M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
32.00 MXN |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About ProKidney Corp.
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
33K%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
29K%
|
19.0
|
|
NASDAQ: NTRA
|
$27.6B
5K%
|
-
|
|
NYSE: IQV
|
$26.3B
5K%
|
20.0
|
|
NASDAQ: UTHR
|
$25.03B
4K%
|
20.4
|
|
NASDAQ: MRNA
|
$18.13B
3K%
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
EBR: ARGX
|
$47.84B
9K%
41.39B EUR
|
39.9
|
|
KRX: 207940
|
$44.84B
8K%
68.19T KRW
|
35.5
|
|
ASX: CSL
|
$42.36B
8K%
60.27B AUD
|
29.3
|
|
SIX: LONN
|
$42.3B
8K%
33.71B CHF
|
37.2
|
|
KRX: 068270
|
$28.11B
5K%
42.76T KRW
|
43.8
|
|
NASDAQ: BNTX
|
$25.69B
5K%
|
-
|
chevron_leftBack